181 related articles for article (PubMed ID: 19317271)
1. Peritoneal implantations of papillary serous ovarian cystadenocarcinoma 13 days after initial laparoscopic treatment for a presumed benign ovarian cyst.
Papoutsis D; Rodolakis A; Haidopoulos D; Sotiropoulou M; Antsaklis A
Eur J Gynaecol Oncol; 2009; 30(1):103-5. PubMed ID: 19317271
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
Dubernard G; Morice P; Rey A; Camatte S; Fourchotte V; Thoury A; Pomel C; Pautier P; Lhommé C; Duvillard P; Castaigne D
Eur J Surg Oncol; 2004 Nov; 30(9):976-81. PubMed ID: 15498644
[TBL] [Abstract][Full Text] [Related]
3. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
[TBL] [Abstract][Full Text] [Related]
4. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 37-2004. A 52-year-old woman with postmenopausal bleeding and a cystic ovarian mass.
Penson RT; Sahani D; Bell DA
N Engl J Med; 2004 Dec; 351(24):2531-8. PubMed ID: 15590956
[No Abstract] [Full Text] [Related]
5. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
[TBL] [Abstract][Full Text] [Related]
6. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.
Santillan A; Kim YW; Zahurak ML; Gardner GJ; Giuntoli RL; Shih IM; Bristow RE
Int J Gynecol Cancer; 2007; 17(3):601-6. PubMed ID: 17504374
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
Gordon AN; Asmar L; Messing MJ; Street DG; Pippitt CH; Bailey CL; Savage J; Young JA
Gynecol Oncol; 2004 Aug; 94(2):533-9. PubMed ID: 15297200
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian cancer.
Méndez LE; Mueller A; Salom E; González-Quintero VH
Obstet Gynecol; 2003 Nov; 102(5 Pt 2):1200-2. PubMed ID: 14607056
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.
Matulonis U; Campos S; Duska L; Fuller A; Berkowitz R; Gore S; Roche M; Colella T; Lee H; Seiden MV; ;
Gynecol Oncol; 2003 Nov; 91(2):293-8. PubMed ID: 14599858
[TBL] [Abstract][Full Text] [Related]
10. Surgery as sole treatment for serous borderline tumors of the ovary with noninvasive implants.
Lackman F; Carey MS; Kirk ME; McLachlin CM; Elit L
Gynecol Oncol; 2003 Aug; 90(2):407-12. PubMed ID: 12893209
[TBL] [Abstract][Full Text] [Related]
11. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin.
Le TD; Yamada SD; Rutgers JL; DiSaia PJ
Gynecol Oncol; 1999 Jun; 73(3):461-3. PubMed ID: 10366480
[TBL] [Abstract][Full Text] [Related]
12. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).
Fields AL; Einstein MH; Novetsky AP; Gebb J; Goldberg GL
Gynecol Oncol; 2008 Jan; 108(1):201-6. PubMed ID: 17997145
[TBL] [Abstract][Full Text] [Related]
13. Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma.
Obermair A; Mileshkin L; Bolz K; Kondalsamy-Chennakesavan S; Cheuk R; Vasey P; Wyld D; Goh J; Nicklin JL; Perrin LC; Sykes P; Janda M
Gynecol Oncol; 2011 Feb; 120(2):179-84. PubMed ID: 21126755
[TBL] [Abstract][Full Text] [Related]
14. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
Kiess AP; Damast S; Makker V; Kollmeier MA; Gardner GJ; Aghajanian C; Abu-Rustum NR; Barakat RR; Alektiar KM
Gynecol Oncol; 2012 Nov; 127(2):321-5. PubMed ID: 22850412
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of clinical characteristics of extraovarian peritoneal serous papillary carcinoma with papillary serous ovarian carcinoma].
Peng YZ; Shen K; Wu M; Huang HF; Pan LY; Yang JX; Lang JH
Zhonghua Fu Chan Ke Za Zhi; 2005 Apr; 40(4):243-5. PubMed ID: 15924670
[TBL] [Abstract][Full Text] [Related]
16. Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy?
Bakkum-Gamez JN; Richardson DL; Seamon LG; Aletti GD; Powless CA; Keeney GL; O'Malley DM; Cliby WA
Int J Gynecol Cancer; 2010 Oct; 20(7):1125-31. PubMed ID: 21495213
[TBL] [Abstract][Full Text] [Related]
17. Papillary serous adenocarcinoma of the uterine cervix: a case report.
Yüksel H; Sezer SD; Küçük M; Riza Obadaşi A; Döger FK
Eur J Gynaecol Oncol; 2011; 32(2):240-2. PubMed ID: 21614930
[TBL] [Abstract][Full Text] [Related]
18. Bilateral micropapillary serous carcinoma of the ovary: a case report.
Gupta R; Singh S; Nigam S
Arch Gynecol Obstet; 2007 May; 275(5):401-4. PubMed ID: 17031658
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer?
Ayhan A; Taskiran C; Yigit-Celik N; Bozdag G; Gultekin M; Usubutun A; Guler N; Yuce K
Int J Gynecol Cancer; 2006; 16(2):484-9. PubMed ID: 16681715
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
Batman S; Bohn J; Weisenberger MW; Hersh A; Bruegl A; Caughey A; Winter W
Gynecol Oncol; 2021 Jan; 160(1):214-218. PubMed ID: 33393480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]